Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease

Rationale: The Scleroderma Lung Study enrolled 158 patients with scleroderma-related interstitial lung disease in a placebo-controlled trial of oral cyclophosphamide (CYC). Although treatment-related benefits in pulmonary function, skin scores, and patient-centered outcomes were demonstrated after 1...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Tashkin, Donald P., Elashoff, Robert, Clements, Philip J., Roth, Michael D., Furst, Daniel E., Silver, Richard M., Goldin, Jonathan, Arriola, Edgar, Strange, Charlie, Bolster, Marcy B., Seibold, James R., Riley, David J., Hsu, Vivien M., Varga, John, Schraufnagel, Dean, Theodore, Arthur, Simms, Robert, Wise, Robert, Wigley, Fred, White, Barbara, Steen, Virginia, Read, Charles, Mayes, Maureen, Parsley, Ed, Mubarak, Kamal, Connolly, M. Kari, Golden, Jeffrey, Olman, Mitchell, Fessler, Barri, Rothfield, Naomi, Metersky, Mark, Khanna, Dinesh, Li, Ning, Li, Gang
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: American Thoracic Society 2007
विषय:
E. Interstitial Lung Disease
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC2078679/
https://ncbi.nlm.nih.gov/pubmed/17717203
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1164/rccm.200702-326OC
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन